Volume 272, Number 36, Issue of September 5, 1997 pp. 22373-22376
©1997 by The American Society for Biochemistry and Molecular Biology, Inc.

MINIREVIEW:
Na⁺/H⁺ Exchangers of Mammalian Cells^*

John Orlowski ^§ and Sergio Grinstein ^¶

From the  Department of Physiology, McGill University, Montreal H3G 1Y6 and ^¶ Division of Cell Biology, Hospital for Sick Children, Toronto M5G 1X8, Canada

INTRODUCTION

The Na⁺/H⁺ Exchanger Gene Family

Structural Features

Tissue and Subcellular Distribution

Basic Functional Properties

Regulation of NHE Activity

FOOTNOTES

REFERENCES

INTRODUCTION

Ejection of intracellular H⁺ in exchange for external Na⁺ is the most effective means of eliminating excess acid from actively metabolizing cells. Na⁺/H⁺ exchange is also crucial for the regulation of the cellular volume and for the reabsorption of NaCl across renal, intestinal, and other epithelia. This remarkable array of essential functions is carried out by a family of antiporters, known generically as Na⁺/H⁺ exchangers (NHEs).¹ These are highly regulated (glyco)phosphoproteins present in virtually all mammalian tissues and species studied to date. The intent of this review is to provide a concise update of the structure, distribution, and regulation of the activity of the known members of the mammalian NHE family.

The Na⁺/H⁺ Exchanger Gene Family

In mammalian cells, NHE activity is localized to both the plasma membrane (1, 2) and the mitochondrial inner membrane (3). To date, five NHE isoforms (NHE1-NHE5) have been identified (4-8). In addition, a novel isoform (NHE6) was recently isolated and is still incompletely characterized.² These transporters are derived from distinct genes that are dispersed throughout the mammalian genome, with no clear evidence of alternative splicing of single mRNA transcripts (reviewed in Ref. 9). A variant rat NHE2 cDNA lacking the coding sequences for the N-terminal 116 amino acids was isolated and postulated to be derived from an alternatively spliced transcript (10). However, the possibility remains that this cDNA represents a partially processed RNA transcript retaining an intron sequence at its 5 end. Overall, NHE1-NHE5 share 34-60% amino acid identity, their predicted molecular mass ranging from 81 to 93 kDa. The recently identified NHE6 shows only 20% identity to the other isoforms.

Structural Features

Based on their primary structure, a similar membrane topology can be predicted for all isoforms, with 10-12 membrane-spanning (M) regions at the N terminus and a large cytoplasmic region at the C terminus. Although the precise topological organization of the NHEs remains uncertain, a tentative model showing 12 transmembrane segments is illustrated in Fig. 1. The N-terminal residues resemble a putative signal peptide sequence that may be cleaved during protein maturation. The membrane-spanning segments M3-M12 share a great deal of identity among the various isoforms. Of these M6 and M7 are most highly conserved (95% identity), suggesting that this region participates in the transport of Na⁺ and H⁺ across the membrane. By contrast, the highly hydrophilic C-terminal region exhibits a lower degree of similarity among isoforms (24-56% identity). This entire domain is seemingly oriented toward the cytosol (Fig. 1), since it is inaccessible to extracellular antibodies or proteases (9).³

Less is known about the tertiary or quaternary structure of the NHEs, although recent evidence suggests that they exist in the membrane as homodimers (11, 12). While the precise location of the contact sites is yet to be defined, the monomers appear to interact at the level of the putative transmembranous region (12) and may be linked by disulfide bonding (11).

Examination of the primary structures of the NHE isoforms reveals several potential glycosylation sites. NHE1 contains both N- and O-glycosylated residues, and mutation of Asn-75 abolishes the N-linked glycosylation (13). In contrast, rabbit NHE2 exhibits only O-linked glycosylation (14) and NHE3 appears not to be glycosylated (13, 15) (Fig. 1). The state of glycosylation of NHE4-NHE6 is unknown.

Glycosylation has been implicated in the proper biosynthetic processing and transit of ion transport proteins to the membrane surface (16), but its role in the case of the NHEs is not evident. Removal of the carbohydrate moieties of NHE1 and NHE2 had no apparent effect on the rate of ion exchange in either membrane vesicles (17) or transfected cells (13, 14).

Tissue and Subcellular Distribution

NHE1 mRNA is expressed in virtually all tissues and cells, where it most likely fulfills "housekeeping" functions including the maintenance of the cytosolic pH (pH_i) and of cellular volume (see Refs. 9 and 18 for reviews). In epithelial cells, NHE1 is largely restricted to the basolateral domain. NHE2, NHE3, and NHE4 mRNAs show a more limited pattern of expression. They are preferentially found in the gastrointestinal tract and in the kidney (5, 6, 8). The targeting of NHE2 in polarized renal and intestinal epithelial cells is controversial, with some studies reporting basolateral (19) and others apical (brush border) localization (20). Its precise physiological roles are unclear, but when transfected into mutagenized cells devoid of endogenous NHE activity, NHE2 is capable of regulating pH_i, cellular volume, and proliferation in a manner resembling NHE1 (21). Immunological studies have localized NHE3 to the apical membranes of renal proximal tubule (15) and intestinal (20, 22) epithelia, implicating this isoform in Na⁺ absorption. The accompanying luminal secretion of H⁺ is essential for HCO₃ reabsorption in renal tubules. NHE4 is highly abundant in the stomach (5) and is also found in the collecting tubule of the renal inner medulla (23). This latter region is normally exposed to high osmolarity, and NHE4 may therefore play a specialized role in the volume homeostasis of these cells (23). Unlike the other isoforms, NHE5 resides in a selected number of nonepithelial tissues (brain > spleen  testis > skeletal muscle) (7) and may represent the amiloride-insensitive NHE variant reported in hippocampal neurons (24). NHE6 is expressed in several human tissues examined, with the highest levels found in brain and skeletal muscle.⁴

Immunolocalization and subcellular fractionation studies have provided initial indications that the antiporters are not distributed homogeneously or even exclusively within the plasma membrane. Though present throughout the surface membrane of adherent fibroblasts, NHE1 was found to accumulate along the border of lamellipodia (25). Vinculin, talin, and F-actin were concentrated at sites of NHE1 accumulation, suggesting that the antiporters can be sequestered in specialized regions by interacting with the cytoskeleton. In this context, it is noteworthy that NHE is activated by engagement of integrins (26). Cross-linking of these adherence receptors may mediate not only the activation but also the redistribution of the antiporters.

Functional analysis of subcellular fractions initially suggested that Na⁺/H⁺ exchangers are present in endomembrane compartments as well. Exchange activity was detected in renal (27) and hepatic (28) endosomes, although the hallmark sensitivity of NHE to amiloride (see below) was not evident. This could be an indication that NHE3, a highly amiloride-resistant isoform, was the species internalized, at least in the kidney. Accordingly, recent immunohistochemical determinations using antibodies specific for NHE3 detected antiporters not only on the microvillar membrane of renal tubular cells but also in a population of subapical vesicles (Fig. 2).⁵ Interestingly, pronounced intracellular staining is also observed when NHE3 is heterologously transfected into antiport-deficient non-epithelial cells. Staining is predominant in a juxtanuclear cluster of vesicles that co-localize with transferrin receptors and with cellubrevin, markers of recycling endosomes (Fig. 2). Internalization motifs present in the cytosolic tail of NHE3 may target this isoform to endosomes, where it could serve as a functional reservoir of spare transporters.

Its wide tissue distribution and greater structural divergence make NHE6 a good candidate for the mitochondrial inner membrane NHE. This mitochondrial exchanger is responsible for extruding Na⁺ from the alkaline matrix of respiring mitochondria (3, 29) and, as such, may contribute to organellar volume homeostasis. Mitochondrial NHE is also indirectly involved in facilitating the efflux of Ca²⁺ and NH₄⁺ from the matrix.

Basic Functional Properties

In native systems, the rate of Na⁺/H⁺ exchange has generally been found to have a hyperbolic dependence on the external Na⁺ concentration ([Na⁺]_o), exhibiting simple Michaelis-Menten kinetics (1). A similar kinetic profile is observed for NHE1, NHE2, and NHE3 when expressed heterologously in fibroblasts (30, 31). In contrast, NHE4 exhibits a sigmoidal dependence on [Na⁺]_o, although the functional significance of this is unclear (32). The affinity of the NHE isoforms for Na⁺ ranges between 5 and 50 mM.

One of the identifying features of the NHE is its exquisite sensitivity to the intracellular pH. The exchangers are allosterically activated by cytosolic H⁺, promoting the rapid extrusion of acid once intracellular pH drops below a threshold level (33). This feature is conserved in the NHE isoforms examined to date (NHE1-NHE3), although the apparent H⁺ sensitivity, which determines the "set point" for activation, varies between isoforms (30, 31). Deletion mutagenesis studies suggested that the N-terminal transmembranous region of human NHE1 contains the H⁺ sensor site, whereas the C-terminal cytoplasmic domain modulates the value of the set point (34). However, other data indicate that this delineation of structural and functional domains may be simplistic (35).

Kinetic as well as thermodynamic considerations indicate that the activity of the mammalian exchangers is electroneutral (1:1 stoichiometry) (see Ref. 36 for review). Nevertheless, the notion of electroneutrality was recently challenged by the observation that antiport activation in the colon was associated with sizable transepithelial currents (37). However, detailed analysis of similar currents in cultured mammalian cells revealed that they were mediated by a separate proton conductance that is very sensitive to local changes in [H⁺], which can result from activation of the exchangers (38).

The NHE is a known target for inhibition by the diuretic compound amiloride and its analogs (39) and by benzoyl guanidinium compounds (e.g. HOE694) (40, 41). The NHE isoforms vary greatly in their sensitivity to these drugs. The apparent affinities of the plasmalemmal isoforms for a defined inhibitor can span up to 4 orders of magnitude, generally following the order: NHE1 > NHE2  NHE3 > NHE4 (30, 32, 40, 41). In contrast, the mitochondrial NHE is relatively insensitive to amiloride but is effectively inhibited by its analog, benzamil (29). Other pharmacological agents such as cimetidine, clonidine, and harmaline also exhibit differential affinities for the NHE isoforms (30). While these compounds are chemically unrelated to amiloride or HOE694, they possess either an imidazoline or guanidinium moiety and hence bear some structural similarity.

Inhibition by amiloride derivatives, cimetidine, and HOE694 is reduced by high external Na⁺, suggesting that these compounds bind near the external (Na⁺) transport site (36, 40). However, other kinetic (42) and genetic selection (43) studies suggest that the Na⁺- and amiloride-binding sites may not be completely identical. Indeed, recent site-directed mutagenesis studies (44, 45) and analysis of NHE chimeras (41) have shown that residues in the predicted M4 and M9 segments contribute to drug sensitivity (Fig. 1) without affecting Na⁺ affinity.

Fluxes through the antiporter are driven by the combined chemical gradients of Na⁺ and H⁺ and hence do not directly consume metabolic energy. Nevertheless, ATP appears to be required for optimal Na⁺/H⁺ exchange. Procedures that reduce intracellular ATP levels drastically inhibit exchange in a variety of native systems and in antiport-deficient cells transfected with either NHE1, -2, or -3 (9, 21, 46). Metabolic depletion appears to depress the rate of transport at least in part by reducing the affinity of the exchangers for intracellular H⁺ (9), without altering the number of plasmalemmal transporters.

Studies of truncation mutants led to the suggestion that constitutive phosphorylation of the cytosolic domain of NHE1 is essential for optimal function (9), thereby accounting for the continued requirement for ATP. Subsequent analysis revealed, however, that the activity changes in metabolically depleted cells are not accompanied by detectable alterations in the phosphorylation pattern of the antiporter (47). Moreover, more detailed mutagenesis studies indicate that at least part of the responsiveness to ATP persists following elimination of all the identified phosphorylation sites of NHE1 (9, 47). Comparable studies have not been reported for other isoforms, but NHE3 remains sensitive to ATP even after truncation of a large part of its cytosolic domain (48).

Because the effect of ATP appears not to involve direct phosphorylation of the antiporters, an ancillary regulatory protein has been invoked. In fact, preliminary experiments indicate that the ATP sensitivity of the exchange is absent in resealed ghosts prepared from red blood cells,⁶ implying that a critical factor has been lost or inactivated during the transient osmotic permeabilization. The nature of this putative factor is unclear, but protein or lipid kinases are attractive possibilities. Alternatively, cytoskeletal components may be involved, since a major rearrangement of F-actin is known to occur upon ATP depletion. The mechanism underlying ATP dependence is likely to be complex, in that the response is partially supported by non-hydrolyzable analogs of the nucleotide (49).

Regulation of NHE Activity

Members of the NHE family display remarkable functional versatility. They are modulated by agents that target primarily tyrosine kinases and also by agonists of Ser/Thr kinases including protein kinases A (PKA) and C (PKC). In addition, they are sensitive to increases in cytosolic [Ca²⁺] and to changes in cell volume. A brief discussion of regulatory mechanisms is presented below.

Regulation of activity can be most simply explained by direct phosphorylation of the antiporters. Indeed, perusal of their primary sequence reveals the existence of consensus sites for phosphorylation by PKA and/or PKC, as well as multiple sites that are suitable substrates for CaM kinase and for proline-directed Ser/Thr kinases (see Ref. 18 for detailed listing). The latter include the mitogen-activated protein kinases, which have recently been implicated in the activation of the antiporter (50, 51).

Tyrosine phosphorylation of the exchangers has not been detected, but the anticipated phosphorylation on Ser residues was borne out experimentally (9, 47, 51). NHE1 was found to be constitutively phosphorylated in resting cells, and further phosphorylation occurred upon addition of growth factors, phorbol esters, or phosphatase inhibitors (see Ref. 9 for review). Multiple phosphorylation sites were detected, all localized to the region of the cytosolic tail distal to residue 635. Similarly, NHE3 was reported to be phosphorylated in untreated cells, and additional phosphorylation occurred following elevation of cAMP (52).

However attractive, the notion that the activity of the antiporters is modulated exclusively by their direct phosphorylation appears simplistic, as it fails to account for the following observations: (i) differential responses have been reported for individual isoforms depending on the cellular expression context (cf. Refs. 30 and 31); (ii) in the case of NHE1 at least part of the regulation by growth factors persists in truncated mutants lacking all the known phosphorylation sites; and (iii) some stimuli activate the antiporter without detectable changes in phosphorylation. One must therefore consider the possibility that regulation results from interaction with other cellular components and that constitutive phosphorylation of the antiporters may facilitate this interaction. Indeed, a variety of proteins capable of associating with different isoforms of the NHE have been identified in recent years. These are illustrated in Fig. 1 and are discussed below.

The cytosolic tail of NHE1 contains two domains capable of binding calmodulin with high (CaM-A, K_d 20 nM) or low (CaM-B, K_d 350 nM) affinity. These are amphiphilic regions rich in basic side chains that likely assume -helical structure. The high affinity CaM-A domain (residues 636-656) is thought to be important in transport regulation. Deletion of this domain segment renders the exchanger constitutively stimulated, as if cytosolic [Ca²⁺] were continuously elevated. It has therefore been suggested that, at basal [Ca²⁺] levels, the unoccupied CaM-A-binding domain exerts on the exchanger an autoinhibitory effect that is relieved upon ligand binding (53).

Only NHE1 has been convincingly shown to be regulated by CaM. Nevertheless, the transmembrane regions of other isoforms can respond to conformational changes of the tail induced by CaM, since insertion of the CaM-binding domain of NHE1 conferred [Ca²⁺] sensitivity to NHE3 (54).

A second Ca²⁺-binding protein was recently found to interact with NHE1. A calcineurin B homolog protein (CHP) can associate with the cytosolic tail of the antiporter near its site of emergence from the bilayer (residues 567-635; see Fig. 1 and Ref. 55). Binding of CHP exerts an inhibitory effect on NHE1, although it remains unclear whether Ca²⁺ is required for this interaction. CHP appears to be constitutively phosphorylated, and stimulation of transport is accompanied by its dephosphorylation. This prompted the suggestion that the phosphoprotein is normally associated with the antiporter, thereby exerting a suppressive effect, and that dissociation upon dephosphorylation may lead to activation of Na⁺/H⁺ exchange (55). Independent experiments detected a polypeptide of 24 kDa, the approximate size of CHP, constitutively associated with NHE1 in several cell types (56).

Yet another protein, hsp70, has been reported to interact with NHE1 (57). Because hsp70 is a molecular chaperone, this interaction may reflect mainly an intermediate stage in the biosynthesis of NHE1. On the other hand, because the association is reversed by MgATP (57), it is tempting to speculate that hsp70 may bind also to mature NHE1 in metabolically depleted cells, perhaps accounting for the ATP dependence of the exchanger.

Proteins associating with NHE2 have not been identified to date. However, two proline-rich domains (⁷⁴³PPSVTPAP⁷⁵⁰ and ⁷⁸⁷PPKPPP⁷⁹²) that resemble SH3-binding domains are present in the C-terminal region. Proline-rich SH3-binding domains have been found to mediate the apical targeting of epithelial Na⁺ channels (58) and may perform a similar function in NHE2.

The apical exchanger of renal epithelial cells, most likely NHE3, also interacts with at least one protein (RF in Fig. 1). Fractionation and reconstitution experiments suggested that a distinct dissociable cofactor is essential for PKA to inhibit the exchanger (59). Subsequent studies identified this cofactor as a phosphoprotein of 42-44 kDa, which is a substrate for PKA phosphorylation (60). It is not clear whether PKA-mediated phosphorylation of NHE3 itself is required for the inhibitory interaction. In addition, NHE3 contains a potential PDZ binding motif (THM) at its very C-terminal end. A related consensus sequence (Thr/Ser-X-Val-COO) is recognized by PDZ domains present in submembrane complexes that mediate the clustering of ion channels or junctional proteins (61).

Transfection as well as microinjection experiments provided evidence that NHE activity is regulated by both heterotrimeric and small GTP-binding proteins. Activated forms of G_q, G₁₂, and G₁₃ have been shown to activate Na⁺/H⁺ exchange (62, 63). In the case of G₁₃ the effect is mediated by RhoA and/or Cdc42, which in turn activate MEKK-1 (64). Accordingly, transfection of activated (GTPase-deficient) forms of these Rho family members, or of Rac1, recapitulate the stimulation of the antiport observed in cells stimulated by hormones or growth factors.

Members of other families of small GTP-binding proteins also induce activation of transport through NHE. In particular, oncogenic forms of Ras greatly enhance the intracellular [H⁺] sensitivity of the antiporter (65). This seemingly results from downstream activation of Raf, MEK1 and/or -2, and mitogen-activated protein kinases of the Erk group (51, 64).

The role of amino phospholipids in antiport function was explored recently (49). This study was triggered by a report that loss of lipid asymmetry drastically inhibited a related transporter, the Na⁺/Ca²⁺ exchanger. Nevertheless, inhibition of the "flippase" that maintains amino phospholipid asymmetry across the plasmalemma had little effect on NHE (49).

There is no evidence that the level of phosphatidylinositol 4,5-bisphosphate, another activator of Na/Ca²⁺ exchange, dictates the rate of NHE. However, there are indications that other products of phosphoinositide metabolism play an important role in transport regulation. The products of the hydrolysis of phosphatidylinositol 4,5-bisphosphate by phospholipase C can stimulate NHE. Both inositol 1,4,5-trisphosphate-mediated [Ca²⁺] changes and stimulation of PKC by diacylglycerol and other inositide derivatives can activate the exchanger. More recently, evidence was also presented that phosphatidylinositol 3-kinase is required for stimulation of the antiporter by growth factors (66, 67). Stimulation of NHE was reduced or eliminated not only by pharmacological inhibition of the kinase but also by point mutations specifically abolishing its interaction with growth factor receptors.

Fluxes of sugar and H⁺ pumping are effectively regulated in various tissues by recruitment of transporters from endomembrane stores to the plasmalemma. This attractive paradigm may apply also to the regulation of NHE, particularly in the case of NHE3, which is believed to reside in intracellular vesicles (see above). Indeed, agents and conditions that induce or modulate NHE activity are known to alter the rates of endo- or exocytosis or effect redistribution of vesicles within cells. These include cAMP, the products of phosphatidylinositol 3-kinase, and cytosolic acidification. The model of regulation of NHE by vesicular traffic is being tested by ongoing work, but no experimental support can be offered at present.

FOOTNOTES

REFERENCES

1. Mahnensmith, R. L., and Aronson, P. S. (1985) Circ. Res. 56, 773-788 [Abstract/Free Full Text]
2. Grinstein, S., Rotin, D., and Mason, M. J. (1989) Biochim. Biophys. Acta 988, 73-97 [Medline] [Order article via Infotrieve]
3. Garlid, K. D. (1988) Adv. Exp. Med. Biol. 232, 37-46 [Medline] [Order article via Infotrieve]
4. Sardet, C., Franchi, A., and Pouyssègur, J. (1989) Cell 56, 271-280 [CrossRef][Medline] [Order article via Infotrieve]
5. Orlowski, J., Kandasamy, R. A., and Shull, G. E. (1992) J. Biol. Chem. 267, 9331-9339 [Abstract/Free Full Text]
6. Wang, Z., Orlowski, J., and Shull, G. E. (1993) J. Biol. Chem. 268, 11925-11928 [Abstract/Free Full Text]
7. Klanke, C. A., Su, Y. R., Callen, D. F., Wang, Z., Meneton, P., Baird, N., Kandasamy, R. A., Orlowski, J., Otterud, B. E., Leppert, M., Shull, G. E., and Menon, A. G. (1995) Genomics 25, 615-622 [CrossRef][Medline] [Order article via Infotrieve]
8. Tse, C.-M., Levine, S., Yun, C., Brant, S., Counillon, L. T., Pouyssègur, J., and Donowitz, M. (1993) J. Membr. Biol. 135, 93-108 [Medline] [Order article via Infotrieve]
9. Wakabayashi, S., Shigekawa, M., and Pouyssègur, J. (1997) Physiol. Rev. 77, 51-74 [Abstract/Free Full Text]
10. Collins, J. F., Honda, T., Knobel, S., Bulus, N. M., Conary, J., DuBois, R., and Ghishan, F. K. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 3938-3942 [Abstract/Free Full Text]
11. Fliegel, L., Haworth, R. S., and Dyck, J. R. B. (1993) Biochem. J. 289, 101-107
12. Fafournoux, P., Noel, J., and Pouyssègur, J. (1994) J. Biol. Chem. 269, 2589-2596 [Abstract/Free Full Text]
13. Counillon, L., Pouyssègur, J., and Reithmeier, R. A. F. (1994) Biochemistry 33, 10463-10469 [CrossRef][Medline] [Order article via Infotrieve]
14. Tse, C.-M., Levine, S. A., Yun, C. H. C., Khurana, S., and Donowitz, M. (1994) Biochemistry 33, 12954-12961 [CrossRef][Medline] [Order article via Infotrieve]
15. Biemesderfer, D., Pizzonia, J., Abu-Alfa, A., Exner, M., Reilly, R., Igarashi, P., and Aronson, P. S. (1993) Am. J. Physiol. 265, F736-F742 [Abstract/Free Full Text]
16. Reithmeier, R. A. F. (1994) Curr. Opin. Cell Biol. 6, 583-594 [CrossRef][Medline] [Order article via Infotrieve]
17. Haworth, R. S., Frohlich, O., and Fliegel, L. (1993) Biochem. J. 289, 637-640
18. Fliegel, L., and Frohlich, O. (1993) Biochem. J. 296, 273-285
19. Soleimani, M., Singh, G., Bizal, G. L., Gullans, S. R., and McAteer, J. A. (1994) J. Biol. Chem. 269, 27973-27978 [Abstract/Free Full Text]
20. Hoogerwerf, W. A., Tsao, S. C., Devuyst, O., Levine, S. A., Yun, C. H. C., Yip, J. W., Cohen, M. E., Wilson, P. D., Lazenby, A. J., Tse, C. M., and Donowitz, M. (1996) Am. J. Physiol. 270, G29-G41 [Abstract/Free Full Text]
21. Kapus, A., Grinstein, S., Wasan, S., Kandasamy, R. A., and Orlowski, J. (1994) J. Biol. Chem. 269, 23544-23552 [Abstract/Free Full Text]
22. Bookstein, C., DePaoli, A. M., Xie, Y., Niu, P., Musch, M. W., Rao, M. C., and Chang, E. B. (1994) J. Clin. Invest. 93, 106-113
23. Bookstein, C., Musch, M. W., DePaoli, A., Xie, Y., Villereal, M., Rao, M. C., and Chang, E. B. (1994) J. Biol. Chem. 269, 29704-29709 [Abstract/Free Full Text]
24. Raley-Susman, K. M., Cragoe, E. J., Jr., Sapolsky, R. M., and Kopito, R. R. (1991) J. Biol. Chem. 266, 2739-2745 [Abstract/Free Full Text]
25. Grinstein, S., Woodside, M., Waddell, T. K., Downey, G. P., Orlowski, J., Pouyssègur, J., Wong, D. C. P., and Foskett, J. K. (1993) EMBO J. 12, 5209-5218 [Medline] [Order article via Infotrieve]
26. Schwartz, M. A. (1992) Trends Cell Biol. 2, 304-308 [CrossRef][Medline] [Order article via Infotrieve]
27. Van Dyke, R. W. (1995) Am. J. Physiol. 269, C943-C954 [Abstract/Free Full Text]
28. Hensley, C., Bradley, M., and Mircheff, A. K. (1990) Kidney Int. 37, 707-716 [Medline] [Order article via Infotrieve]
29. Brierley, G. P., Davis, M. H., Cragoe, E. J., Jr., and Jung, D. W. (1989) Biochemistry 28, 4337-4354
30. Orlowski, J. (1993) J. Biol. Chem. 268, 16369-16377 [Abstract/Free Full Text]
31. Levine, S. A., Montrose, M. H., Tse, C. M., and Donowitz, M. (1993) J. Biol. Chem. 268, 25527-25535 [Abstract/Free Full Text]
32. Bookstein, C., Musch, M. W., DePaoli, A., Xie, Y., Rabenau, K., Villereal, M., Rao, M. C., and Chang, E. B. (1996) Am. J. Physiol. 271, C1629-C1638 [Abstract/Free Full Text]
33. Aronson, P. S., Nee, J., and Suhm, M. A. (1982) Nature 299, 161-163 [CrossRef][Medline] [Order article via Infotrieve]
34. Wakabayashi, S., Fafournoux, P., Sardet, C., and Pouyssègur, J. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2424-2428 [Abstract/Free Full Text]
35. Bianchini, L., Kapus, A., Lukacs, G., Wasan, S., Wakabayashi, S., Pouyssègur, J., Yu, F. H., Orlowski, J., and Grinstein, S. (1995) Am. J. Physiol. 269, C998-C1007 [Abstract/Free Full Text]
36. Aronson, P. S. (1985) Annu. Rev. Physiol. 47, 545-560 [CrossRef][Medline] [Order article via Infotrieve]
37. Post, M. A., and Dawson, D. C. (1994) J. Gen. Physiol. 103, 895-916 [Abstract/Free Full Text]
38. Demaurex, N., Orlowski, J., Brisseau, G., Woodside, M., and Grinstein, S. (1995) J. Gen. Physiol. 106, 85-111 [Abstract/Free Full Text]
39. Kleyman, T. R., and Cragoe, E. J., Jr. (1988) J. Membr. Biol. 105, 1-21 [CrossRef][Medline] [Order article via Infotrieve]
40. Counillon, L., Scholz, W., Lang, H. J., and Pouyssègur, J. (1993) Mol. Pharmacol. 44, 1041-1045 [Abstract]
41. Orlowski, J., and Kandasamy, R. A. (1996) J. Biol. Chem. 271, 19922-19927 [Abstract/Free Full Text]
42. Ives, H. E., Yee, V. J., and Warnock, D. G. (1983) J. Biol. Chem. 258, 9710-9716 [Abstract/Free Full Text]
43. Franchi, A., Cragoe, E. J., Jr., and Pouyssègur, J. (1986) J. Biol. Chem. 261, 14614-14620 [Abstract/Free Full Text]
44. Counillon, L., Franchi, A., and Pouyssègur, J. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 4508-4512 [Abstract/Free Full Text]
45. Wang, D., Balkovetz, D. F., and Warnock, D. G. (1995) Am. J. Physiol. 269, C392-C402 [Abstract/Free Full Text]
46. Cassel, D., Katz, M., and Rotman, M. (1986) J. Biol. Chem. 261, 5460-5466 [Abstract/Free Full Text]
47. Goss, G. G., Woodside, M., Wakabayashi, S., Pouyssègur, J., Waddell, T., Downey, G. P., and Grinstein, S. (1994) J. Biol. Chem. 269, 8741-8748 [Abstract/Free Full Text]
48. Cabado, A. G., Yu, F. H., Kapus, A., Gergely, L., Grinstein, S., and Orlowski, J. (1996) J. Biol. Chem. 271, 3590-3599 [Abstract/Free Full Text]
49. Demaurex, N., Romanek, R., Orlowski, J., and Grinstein, S. (1997) J. Gen. Physiol. 109, 117-128 [Abstract/Free Full Text]
50. Aharonovitz, O., and Granot, Y. (1996) J. Biol. Chem. 271, 16494-16499 [Abstract/Free Full Text]
51. Bianchini, L., L'Allemain, G., and Pouyssègur, J. (1997) J. Biol. Chem. 272, 271-279 [Abstract/Free Full Text]
52. Moe, O. W., Amemiya, M., and Yamaji, Y. (1995) J. Clin. Invest. 96, 2187-2194
53. Bertrand, B., Wakabayashi, S., Ikeda, T., Pouyssègur, J., and Shigekawa, M. (1994) J. Biol. Chem. 269, 13703-13709 [Abstract/Free Full Text]
54. Wakabayashi, S., Ikeda, T., Noel, J., Schmitt, B., Orlowski, J., Pouyssègur, J., and Shigekawa, M. (1995) J. Biol. Chem. 270, 26460-26465 [Abstract/Free Full Text]
55. Lin, X., and Barber, D. L. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 12631-12636 [Abstract/Free Full Text]
56. Goss, G., Orlowski, J., and Grinstein, S. (1996) Am. J. Physiol. 270, C1493-C1502 [Abstract/Free Full Text]
57. Silva, N. L. C. L., Haworth, R. S., Singh, D., and Fliegel, L. (1995) Biochemistry 34, 10412-10420 [CrossRef][Medline] [Order article via Infotrieve]
58. Rotin, D., Bar-Sagi, D., O'Brodovich, H., Lehto, B. P., Canessa, C., Rossier, B. C., and Downey, G. P. (1994) EMBO J. 13, 4440-4450 [Medline] [Order article via Infotrieve]
59. Weinman, E. J., Steplock, D., and Shenolikar, S. (1993) J. Clin. Invest. 92, 1781-1786
60. Weinman, E. J., Steplock, D., Wang, Y., and Shenolikar, S. (1995) J. Clin. Invest. 95, 2143-2149
61. Harrison, S. C. (1996) Cell 86, 341-343 [CrossRef][Medline] [Order article via Infotrieve]
62. Dhanasekaran, N., Vara Prasad, M. V. V. S., Wadsworth, S. J., Dermott, J. M., and Van Rossum, G. (1994) J. Biol. Chem. 269, 11802-11806 [Abstract/Free Full Text]
63. Lin, X., Voyno-Yasenetskaya, T. A., Hooley, R., Lin, C.-Y., Orlowski, J., and Barber, D. L. (1996) J. Biol. Chem. 271, 22604-22610 [Abstract/Free Full Text]
64. Hooley, R., Yu, C. Y., Symons, M., and Barber, D. L. (1996) J. Biol. Chem. 271, 6152-6158 [Abstract/Free Full Text]
65. Kaplan, D. L., and Boron, W. F. (1994) J. Biol. Chem. 269, 4116-4124 [Abstract/Free Full Text]
66. Ma, Y., Reusch, H. P., Wilson, E., Escobedo, J. A., Williams, L. T., and Ives, H. I. (1994) J. Biol. Chem. 269, 30734-30739 [Abstract/Free Full Text]
67. Khurana, S., Nath, S., Levine, S. A., Tse, C., Cohen, M. E., and Donowitz, M. (1996) J. Biol. Chem. 271, 9919-9927 [Abstract/Free Full Text]